Work

Abstract PS4-06-17: First clinical data of DB-1310 (HER3-targeted antibody-drug-conjugate), in patients with pretreated hormone receptor-positive/HER2-negative breast cancer: efficacy and safety data from a phase 1/2a trial

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps4-06-17

Authors: Y. Yin, A. Spira, H. Lan, M. Zhao, Y. Mao, W. Yao, Y. Sun, J. Wu, X. Sun, S. Liu, H. Mu, K. Wang, Y. Qiu, E. Hamilton

Institutions: Jiangsu Province Hospital, Nanjing Medical University, Ovarian Cancer Canada, Cancer Care Nova Scotia, Nova Scotia Cancer Centre, Brain Repair Centre, University of Electronic Science and Technology of China, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, First Hospital of China Medical University, China Medical University, Jiangnan University, Sichuan Cancer Hospital, Shandong First Medical University, Hainan Medical University, Duality Biotherapeutics, Inc. (China), Sarah Cannon

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129605709

Cites:

Cited by:

Related to: